Clinical Trials The trial involved 227 children and 224 adults, with the significant immune responses in children aged two to five years. Bavarian Nordic has announced encouraging topline results from a clinical trial assessing its MVA-BN mpox/smallpox vaccine in children aged between two and 11 years.
The trial involved 460 participants across two cohorts, examining the immunogenicity and safety of two standard vaccine doses in both paediatric and adult populations aged 18–50 years.
It was jointly funded by the Coalition for Epidemic Preparedness Innovations (CEPI) and took place at various locations in the Democratic Republic of Congo and Uganda.